Consultant Physician
Adult Cystic Fibrosis Department, Royal Brompton Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK., United Kingdom
Dr Imogen Felton MRCP(UK) PhD MBBS BSc. Consultant in Respiratory Medicine and Adult Cystic Fibrosis, Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust, London, UK.
Dr Imogen Felton qualified at Guy's, King's and St Thomas' School of Medicine in 2005, where she also completed an intercalated BSc. in Psychology. She then trained in Respiratory medicine in London, including at St. Thomas’, King’s College and Royal Brompton hospitals. In 2012, Dr Felton was awarded National Institute for Health Research (NIHR) funding for a PhD in respiratory and genomic medicine at Imperial College London and Royal Brompton Hospital with Professors Nicholas Simmonds and Professor William Cookson, studying the fungal respiratory microbiome (mycobiome) in adult cystic fibrosis (CF) and non-CF bronchiectasis.
Dr Felton completed her post-graduate specialist training in 2018 with the CF Trust Fellowship Award, working in adult CF centres in the UK (King's College Hospital, Royal Brompton Hospital and Manchester CF Centre) and in the USA at Cystic Fibrosis Foundation (CFF), Therapeutics Development Network Centre, Children's Research Institute and University of Washington. In 2021, Dr Felton established a unique multi-disciplinary CF-Reproductive and Maternal Health Service in partnership with Obstetricians at Chelsea and Westminster Hospital, London and a broader clinical and academic network with King's Health Partners.
Areas of expertise:
Dr Felton is a respiratory consultant with particular expertise in adults with CF and CFTR-related disorders, including reproductive and maternal medicine and complications relating to CF-fungal infection and related diabetes.
Research interests:
Dr Felton's current research aims focus around CF-Maternal and Reproductive Health , CF-related diabetes and CF-fungal infection both supported by her collaboration as Co-Investigator in two Strategic Research Consortium projects sponsored by the UK CF Trust and the King’s Health Partners Clinical Academic Innovation Fund. She has a particular interest in the impact on patient experiences and clinical outcomes following CFTR-mutation specific modulator therapy during pregnancy and parenthood.